Evaluation of the antianginal effectiveness of trimetazidine in a new dosage form for a single dose, depending on the region of the Russian Federation. ODA trial results

The goal evaluation of the effectiveness of treatment with the new TMZ OD dosage form in different regions of the Russian Federation and regional differences in the clinical characteristics of patients with coronary artery disease included in the observation, the nature of their therapy, the presence and degree of correction of modifiable risk factors in real clinical practice. Material. Used database research ODA (Evaluation of the effectiveness and therapeutic response to Preductal OD 80 mg in everyday practical use for the treatment of stable angina), which was conducted in 56 cities of the Russian Federation. The analysis was carried out in the Central, North-West, Volga districts and regions united by the territorial principle – Southern + North Caucasian + Crimea + Sevastopol and Ural + Siberian + Far Eastern. Results. By region, there were no differences in the ratio of men and women included in the observation, the number of smoking patients (about 15%), overweight (about 80% of patients), arterial hypertension (exceeding 85%),dyslipidemia (over 90%), and atrial fibrillation (met at each 8-10 included patient). The proportion of patients older than 65 years was greater in the Central, North-West and Ural regions. Unfavorable heredity in coronary artery disease is more common in the Southern, Central and Ural regions. More than 2/3 of the patients had low physical activity, and in the South — their number reached ¾ of all included in the observation. The largest number of patients with diabetes was in the Central and North-West regions (every fourth patient), in the Ural region every fifth. The lowest frequency of statin prescribing was in the Volga region. The smallest number of those receiving RAS inhibitors was in the North-West, Ural and South regions. Beta blockers took more than 80% of patients. Only 35% of patients had a target systolic blood pressure. The smallest proportion of people with target blood pressure values was in the NorthWest and South regions. Adding TMZ OD to therapy or replacing previous therapy with trimetazidine on TMZ OD in all regions resulted in a significant (p <0.001) decrease in the incidence of angina attacks by as early as 1 month of therapy and the antianginal effect increased by the third month of treatment. By the third month of treatment, the average frequency of angina attacks was the lowest in the North-Western and Ural regions (significantly lower than even in the Central region) and remained higher only in the Volga region compared to the Central, North-Western and Ural regions. During follow-up, treatment compliance increased significantly in all regions. Conclusion. The fight against major risk factors remains insufficient and efforts should be made to change the situation in all regions of the Russian Federation. The inclusion of trimetazidine in therapy in the new TMZ OD dosage form allows to obtain a pronounced antianginal effect and increase adherence to therapy. Low adherence can be overcome by careful observation and closer contact between doctors and patients.

1. Glezer M.G., Vygodin V.A. Anti-Anginal Effectiveness and Tolerability of Trimetazidine Modified Release 80 Mg Once Daily in Stable Angina Patients in Real-World Practice. Advances in Therapy. 2018;35(9):1368–77. DOI: 10.1007/s12325-018-0756-3

2. Ministry of Health of Russian Federation. Clinical recommendations (CR155). Stable coronary heart disease. 2016. [Internet] 2016. Available at: http://cr.rosminzdrav.ru/#!/schema/133

3. Pogosova N.V., Oganov R.G., Boytsov S.A., Ausheva A.K., Sokolova O Yu., Kursakov A.A. et al. Monitoring the Secondary Prevention of Coronary Artery Disease in Europe and Russia: Results of the Russian Part of the International Multicenter Study EUROASPIRE IV. Kardiologiia. 2015;55(12):99–107.

4. De Backer G, Jankowski P, Kotseva K, Mirrakhimov E, Reiner Ž, Rydén L et al. Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis. 2019;285:135–46. DOI: 10.1016/j.atherosclerosis.2019.03.014

5. Girerd X, Radauceanu A, Achard JM, Fourcade J, Tournier B, Brillet G et al. Evaluation of patient compliance among hypertensive patients treated by specialists. Archives des maladies du coeur et des vaisseaux. 2001;94(8):839–42. PMID: 11575214

6. Von Arnim T. Prognostic significance of transient ischemic episodes: Response to treatment shows improved prognosis Results of the total ischemic burden bisoprolol study (TIBBS) follow-up. Journal of the American College of Cardiology. 1996;28(1):20–4. DOI: 10.1016/0735-1097(96)00122-2

7. Wilhelmsen L, Rosengren A, Hagman M, Lappas G. “Nonspecific” chest pain associated with high long-term mortality: Results from the primary prevention study in göteborg, sweden. Clinical Cardiology. 1998;21(7):477–82. DOI: 10.1002/clc.4960210706

8. Gibbons RJ, Chatterjee K, Daley J, Douglas JS, Fihn SD, Gardin JM et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic Stable Angina). Journal of the American College of Cardiology. 1999;33(7):2092–197. PMID: 10362225

9. Spertus JA, Jones P, McDonell M, Fan V, Fihn SD. Health Status Predicts Long-Term Outcome in Outpatients with Coronary Disease. Circulation. 2002;106(1):43–9. DOI: 10.1161/01.CIR.0000020688.24874.90

10. Chow CK. Prevalence, Awareness, Treatment, and Control of Hypertension in Rural and Urban Communities in High-, Middle-, and Low-Income Countries. JAMA. 2013;310(9):959–68. DOI: 10.1001/jama.2013.184182

11. Kotseva K, Wood D, De Bacquer D, De Backer G, Rydén L, Jennings C et al. EUROASPIRE IV: a European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. European Journal of Preventive Cardiology. 2016;23(6):636–48. DOI: 10.1177/2047487315569401

12. Muromtceva G.A., Kontsevaya A.V., Konstantinov V.V., Artamonova G.V., Gatagonova T. M., Duplyakov D.V. et al. The prevalence of noninfectious disease risk factors in the Russian population in 2012-2013. Results of the ESSE-RF study. Cardiovascular Therapy and Prevention. 2014;13(6):4–11. DOI: 10.15829/1728-8800-2014-6-4-11

13. Boytsov S.A., Balanova Yu.A., Shal’nova S.A., Deev A.D., Artamonova G.V., Gatagonova T.M. et al. Arterial hypertension among persons aged 25-64: prevalence, awareness, treatment and control. By the data from ECCD. Cardiovascular Therapy and Prevention. 2014;13(4):4–14. DOI: 10.15829/1728-8800-2014-4-4-14

14. Glezer M.G., on on behalf of the C- study par, Sechenov First Moscow state medical university, Moscow, Russia. Treatment of patients with stable ischemic heart disease in real clinical practice in Russia. The CHOICE-2 Program. Kardiologiia. 2016;56(5):5–11. DOI: 10.18565/cardio.2016.5.5-11

15. Glezer M.G. LINKOR: results of observational program in patients with myocardial infarction. Kardiologiia. 2013;53(5):74–82.